Search results for " vaccine"
Article
Pharma Investments Reflect Key Industry Trends
GSK is selling its oncology business to Novartis and buying Novartis’ vaccines business (excluding influenza vaccines), and the two companies are combining their over-the-counter businesses.
In Ma…
Article
Operational Excellence: More Than Just Process Improvement
For a vaccine maker, a simultaneous two-site initiative saved a total of $50 million across two facilities. Such transformations can yield a multiplicity of operational, organizational, and financial …
Article
Scaling Up Novel Therapies
“Many processes rely on the culture of adherent cells for producing a range of biological molecules, including viral vaccines, viral vectors for gene therapy, and oncolytic viruses. Producing these th…
Article
Manufacturing of Viral Vectors
Viral vectors are also explored for use in gene and cell therapy and as the basis for prophylactic and therapeutic vaccines. In gene therapy, viral vectors can be used for the delivery of functional g…
Article
Developing an Efficient Adenovirus Downstream Purification Process
Adenovirus is one of the most frequently used viral vectors in the development of therapeutic vaccines and adenovirus is evaluated as vaccine delivery system in many preclinical and clinical studies…
Article
Optimization of Adenovirus Midstream Purification Steps
Adenovirus (AdV)-based vectors are widely evaluated as vaccine delivery system in preclinical and clinical studies for various infectious diseases. In this application note, studies of midstream pur…
Article
3rd BioProcessing Asia Preview: Q&A with John Curling
The program always covers the entire biopharmaceutical spectrum from antibodies and blood plasma products to vaccines as well as biosimilars development. BioProcessing Asia also differentiates itself …
Article
Evaluation of HEK293 Cell Growth and Adenovirus Productivity in HyClone™ CDM4HEK293 Medium
HEK293 cells are susceptible to infection by adenovirus, one of the most frequently used viral vectors in the development of therapeutic vaccines and vaccines against infectious diseases. This applica…
Article
The New World of Biopharmaceutical Manufacturing
Companies are implementing end-to-end single-use platforms for monoclonal antibody, antibody drug conjugate, and vaccine production. Flexible facilities are likely to become an important part of large…
Article
Safety Drives Innovation in Animal-Component-Free Cell-Culture Media Technology
…s that have now become standard for producing recombinant antibodies, therapeutic proteins, and some vaccines. Although the same concerns for safety are ultimately expected to drive other cell-cultur…